Metropolis Healthcare Limited (NSE:METROPOLIS)
India · Delayed Price · Currency is INR | Market Cap | 112.27B +27.4% |
| Revenue (ttm) | 16.46B +23.6% |
| Net Income | 1.90B +31.1% |
| EPS | 9.19 +30.6% |
| Shares Out | 207.33M |
| PE Ratio | 58.92 |
| Forward PE | 44.36 |
| Dividend | 2.00 (0.37%) |
| Ex-Dividend Date | May 19, 2026 |
| Volume | 39,709 |
| Open | 538.00 |
| Previous Close | 541.50 |
| Day's Range | 527.05 - 541.70 |
| 52-Week Range | 411.25 - 600.00 |
| Beta | 0.14 |
| Analysts | Buy |
| Price Target | 608.60 (+14.8%) |
| Earnings Date | May 13, 2026 |
About Metropolis Healthcare
Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India, Africa, South Asia, the Middle East, and internationally. The company offers routine and semi-specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; and clinical trial research, hospital lab management, and home collection services, as well as profiles, blood tests, and soft radiology services. It also provid... [Read more]
Financial Performance
In fiscal year 2026, Metropolis Healthcare's revenue was 16.46 billion, an increase of 23.64% compared to the previous year's 13.31 billion. Earnings were 1.90 billion, an increase of 31.08%.
Financial StatementsNews
Metropolis Healthcare concall update: Management targets 13-15% growth in FY27 despite Q4 miss
Metropolis Healthcare shares traded higher on Thursday after the company’s management maintained a bullish growth outlook for FY27 despite a Q4 miss, with investors taking note of strong year-on-year ...
Metropolis Healthcare Transcript: Q4 25/26
FY 2026 saw 23.6% group revenue growth and margin expansion, driven by Specialty and TruHealth segments, digital channels, and successful integration of acquisitions. Guidance targets 14%-15% CAGR and 27%-28% EBITDA margin over three years, with continued network and digital expansion.
Metropolis Healthcare Quarterly report: Q4 2026
Metropolis Healthcare has published its Q4 2026 quarterly earnings report on May 13, 2026.
Metropolis Healthcare Slides: Q4 2026
Metropolis Healthcare has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 13, 2026.
Metropolis Healthcare Transcript: Q3 25/26
Q3 saw 26% group revenue growth and 29% organic EBITDA growth year-on-year, with strong performance across B2C and B2B segments and expanding margins. Strategic focus on genomics, digital, and network expansion continues, while a 3:1 bonus share issue was announced.
Metropolis Healthcare Quarterly report: Q3 2026
Metropolis Healthcare has published its Q3 2026 quarterly earnings report on February 4, 2026.
Metropolis Healthcare Slides: Q3 2026
Metropolis Healthcare has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 4, 2026.
Metropolis Healthcare Ltd (BOM:542650) Q3 2026: Everything You Need To Know Ahead Of Earnings
Metropolis Healthcare Ltd (BOM:542650) Q3 2026: Everything You Need To Know Ahead Of Earnings
Metropolis Healthcare launches Centre of Genomics to scale precision diagnostics in India
Metropolis Healthcare Limited on Tuesday announced the launch of its Centre of Genomics, marking a strategic expansion of its advanced...
Metropolis Healthcare shares rise over 3% after strong Q3 FY26 business update
Shares of Metropolis Healthcare traded higher in Monday’s session after the diagnostics company reported a strong business performance for the...
Metropolis Healthcare reports 26% revenue growth in Q3 FY26; wellness and specialty segments drive demand
Metropolis Healthcare Limited has reported a strong operating performance in the December quarter of FY26, with consolidated revenue rising around...
Metropolis Healthcare Transcript: Q2 25/26
Group revenue grew 23% year-over-year with strong organic margin expansion and double-digit volume growth. Integration of recent acquisitions is progressing, and guidance for margin and top-line growth is maintained for FY2026.
Metropolis Healthcare Quarterly report: Q2 2026
Metropolis Healthcare has published its Q2 2026 quarterly earnings report on November 6, 2025.
Metropolis Healthcare Slides: Q2 2026
Metropolis Healthcare has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 6, 2025.
Metropolis Healthcare shares jump over 3% as Q2 revenue rises 22.7% YoY to Rs 429 crore, net profit up 13.2%
Metropolis Healthcare shares jumped more than 3% in early trade after the diagnostics company reported a strong set of earnings...
What To Expect From Metropolis Healthcare Ltd (BOM:542650) Q2 2026 Earnings
What To Expect From Metropolis Healthcare Ltd (BOM:542650) Q2 2026 Earnings
Metropolis Healthcare incorporates new subsidiary Metropolis Quality Solutions
Metropolis Healthcare Limited on Tuesday announced the incorporation of a new wholly owned subsidiary, Metropolis Quality Solutions Private Limited, effective September 15, 2025. The newly incorporate...
Metropolis Healthcare shares jump nearly 3% following Q1 results; Company projects over 12% revenue growth in FY26
Shares of Metropolis Healthcare Ltd surged 2.86% to ₹2,065.90 on Monday, adding ₹57.50 in early trade. The stock, listed on NSE, has a market capitalisation of ₹10,513.48 crore and has traded between ...
Metropolis Healthcare Transcript: Q1 25/26
Q1 FY2026 saw 23% group revenue growth and 13.2% organic growth, with margin expansion and strong performance in specialty and preventive diagnostics. Integration of recent acquisitions is on track, and further growth is expected in Tier 2/3 markets and B2C share.
Metropolis Healthcare Quarterly report: Q1 2026
Metropolis Healthcare has published its Q1 2026 quarterly earnings report on August 8, 2025.
Metropolis Healthcare Slides: Q1 2026
Metropolis Healthcare has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on August 8, 2025.
Metropolis Healthcare eyes double-digit growth as B2C gains traction
Nuvama Institutional Equities has reiterated a ‘Buy’ rating on Metropolis Healthcare, maintaining its target price at ₹2,240 per share. The brokerage cited improving business mix, strong B2C performan...
Metropolis Healthcare shares rise over 2% today as specialty and TruHealth segments post strong Q1 growth
On Monday, 7th July, shares of Metropolis Healthcare Ltd gained 2.35% to ₹1,815 on the NSE, rising ₹41.70 from the previous close of ₹1,773.30. The stock moved higher after the company shared its busi...
Dr Lal PathLabs, Metropolis Healthcare shares decline as Amazon Diagnostics enters market
Shares of diagnostic service providers Dr Lal PathLabs and Metropolis Healthcare slipped in Monday’s trade following Amazon India’s announcement of its foray into the diagnostics space. Amazon launche...
Metropolis Healthcare Transcript: Q4 24/25
FY25 saw 12% revenue growth, strong B2C momentum, and three strategic acquisitions to boost North India presence. FY26 guidance is for 25-26% total revenue growth, 100 bps organic margin expansion, and continued focus on operational efficiency and digital transformation.